PHARMACOECONOMIC EVALUATION OF RIBOCICLIB FOR THE FIRST-LINE TREATMENT OF HR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER

PHARMACOECONOMIC EVALUATION OF RIBOCICLIB FOR THE FIRST-LINE TREATMENT OF HR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER

Background. Breast cancer is the most common malignant tumor and accounts for the most number of cancer-related deaths among Russian women. Combination of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor ribociclib and aromatase inhibitor is approved for the first-line treatment of postmenopausal...

Full description

Bibliographic Details
Main Authors: N. A. Avksentyev, M. V. Zhuravleva, E. M. Pazukhina, A. V. Snegovoy, M. Yu. Frolov
Format: Article
Language:Russian
Published: ABV-press 2018-08-01
Series:Опухоли женской репродуктивной системы
Subjects:
рак молочной железы
рибоциклиб
палбоциклиб
фармакоэкономический анализ
влияние на бюджет
анализ «затраты-эффективность»
Online Access:https://ojrs.abvpress.ru/ojrs/article/view/591

Similar Items

Similar Items